Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER Meeting Abstract

  

Authors:	Baselga, J.; Dent, S. F.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Verma, S.; Wilson, T. R.; Jin, H.; Wang, L.; Schimmoller, F.; Hsu, J. Y.; He, J.; DeLaurentiis, M.; Drullinsky, P.; Jacot, W.
Abstract Title:	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
Meeting Title:	54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	36
Issue:	18 Suppl.
Meeting Dates:	2018 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2018-06-20
Language:	English
ACCESSION:	WOS:000443284700006
PROVIDER:	wos
DOI:	10.1200/JCO.2018.36.18_suppl.LBA1006
Notes:	Meeting Abstract: LBA1006 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/137382